NYXH Nyxoah
Company Analysis
Latest News
🟢 Nyxoah is trading 10.69% up as the specific driver remains unclear
Nyxoah is trading 10.69% up at $1.60 on September 28, 2026, with no clear company-specific catalyst identified. - The latest company news was a September 21...
🟢 Nyxoah is trading 9% up
Nyxoah is trading at $1.58, up 8.97% in live trading on September 28, 2026, with no clear company-specific catalyst identified. - The latest company...
🟢 Nyxoah is trading 10% up in pre-market
Nyxoah is trading 10.34% higher at $1.60 in pre-market on September 28, with no clear company-specific catalyst identified. - The latest company announcement...
🟢 Nyxoah is trading 6.9% up in pre-market with no clear catalyst identified
Nyxoah is trading 6.9% higher at $1.55 in pre-market on September 28; no clear company-specific announcement explaining the move was identified. - The latest...
🟢 Nyxoah is trading 10.6% up today as healthcare stocks gain
Nyxoah is trading at $1.41, up 10.6%, as healthcare stocks gain amid renewed biotechnology optimism, acquisition activity, and a supportive regulatory...
🟢 Nyxoah is trading 8.7% up today as healthcare gains 1.27%
Nyxoah is trading at $1.38, up 8.66%, with the move appearing mainly sector-driven. - Healthcare gained 1.27% as renewed biotech optimism, acquisition activity...
🟢 Nyxoah is trading 7.09% up in pre-market
Nyxoah is trading 7.09% higher at $1.36, with no clear company-specific catalyst identified. - Nyxoah closed at $1.27 on September 24, 2026; no clear...
🔴 Nyxoah is trading 5.36% down today as U.S. markets fall
Nyxoah is trading at $1.32 (-5.36%) as U.S. markets fall, creating a risk-off backdrop. - The S&P 500 is down 0.65%, while the Nasdaq is down 1.06%. - Higher...
🟢 Nyxoah is trading 5% up in after-hours trading after CFO departure announcement
Nyxoah is trading 5% up at $1.47 after its September 21, 2026 announcement that CFO John Landry will depart. - Landry’s departure is effective October 2....
🔴 Nyxoah is trading 5% down today after CFO departure effective October 2, 2026
Nyxoah is trading 5% down at $1.41 after CFO John Landry announced his departure, effective October 2, 2026. - Loïc Moreau, the company’s former CFO, will...
🔴 Nyxoah is trading 5.8% down in after-hours trading with no company-specific catalyst identified
Nyxoah is trading 5.81% down now at $1.46 after no new company-specific announcement or earnings release was identified for September 16, 2026. - Earlier...
Cantor Fitzgerald Reiterates Overweight Rating Following Positive Trial Results
Cantor Fitzgerald reiterated its Overweight rating and $6.00 price target for Nyxoah SA on September 4, 2026. The affirmation follows the company's...
🔴 Nyxoah is trading 5.1% down today with no new company-specific catalyst identified
Nyxoah is trading at $1.67 (-5.11%) on September 4, 2026; no new company-specific catalyst directly explaining the decline was identified. - It closed at...
🟢 Nyxoah is trading 18.87% up today after ACCCESS U.S. pivotal study meets primary endpoints
Nyxoah is trading at $1.79, +18.87% after its September 2, 2026 ACCCESS U.S. pivotal study met primary safety and efficacy endpoints. - At 12 months, AHI and...
🟢 Nyxoah is trading 17.85% up in pre-market after ACCCESS study meets safety and efficacy endpoints
Nyxoah is trading 17.85% up at $1.78 after its September 2, 2026 announcement that the ACCCESS U.S. pivotal study met primary safety and efficacy endpoints. -...
Nyxoah's Sleep Apnea Device Aces a Key Trial — But Can a $170 Million Company Turn Clinical Data Into Commercial Traction?
Shares of Nyxoah jumped 11.3% to $1.68 after the Belgian medtech firm reported that its U.S. pivotal trial for a hard-to-treat subset of sleep apnea patients...
🟢 Nyxoah is trading 11.26% up in after-hours trading after ACCCESS study met primary endpoints
Nyxoah is trading $1.68 (+11.26%) after its ACCCESS U.S. pivotal study met primary efficacy and safety endpoints. - Nyxoah announced the results on September...
🟢 Nyxoah is trading 6.7% up in after-hours trading with no confirmed catalyst
Nyxoah is trading 6.66% up now at $1.59 in after-hours trading, versus a $1.49 close on September 1, 2026, with the catalyst unconfirmed. - Investor relations...
🟢 Nyxoah is trading 5% up in pre-market with no clear company-specific catalyst
Nyxoah is trading 5.13% up at $1.64 in pre-market on September 1, 2026, with no clear company-specific catalyst identified. - Investor-relations page lists...
🟢 Nyxoah is trading 5.7% up in pre-market with no fresh company-specific catalyst identified
Nyxoah is trading $1.67 (+5.70%) up now after no fresh company-specific catalyst was identified for August 14, 2026. • The latest identifiable company update...